[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"interventionName\":\"Lifestyle Intervention\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":374},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,45,76,105,133,163,187,208,235,277,299,325,348],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100573099","the-inspire--faith-study-intervention-strategies-for-preserving-intellectual-resilience-and-engagement-100573099",false,"NCT06741865","The INSPIRE -Faith Study: Intervention Strategies for Preserving Intellectual Resilience and Engagement","Intervention Strategies for Preserving Intellectual Resilience and Engagement","INSPIRE -Faith","Inclusion Criteria:\n\n* Age: Participants must be 55 years of age or older.\n* Ethnicity: Focused on African American individuals, but not exclusive.\n* Cognitive Status: Participants must have normal cognitive status, mild cognitive impairment (MCI), or subjective cognitive impairment (SCI).\n* Language: Participants must be fluent in English.\n* Location: Must reside in the Crenshaw, California area or\\* be able to attend study-related activities in this location. \\*online access is available for those not in this area.\n* Willingness to Participate: Participants must be willing to adhere to the study protocol, including attending assessments, participating in interventions, and completing questionnaires.\n\nExclusion Criteria:\n\n* Cognitive Decline: Diagnosis of dementia or severe cognitive impairment that would interfere with the ability to participate in the study.\n* Physical Limitations: Any physical or medical condition that would preclude participation in the lifestyle interventions (e.g., severe mobility issues).\n* Recent Cancer Diagnosis: Diagnosis of cancer within the last three years, excluding stable cases of basal cell or squamous cell carcinoma of the skin, or stable prostate cancer.\n* Pregnancy: Current pregnancy or planning to become pregnant during the study period.\n* Mental Health: Diagnosis of severe psychiatric disorders such as schizophrenia or bipolar disorder that might interfere with participation.\n* Substance Abuse: Current substance abuse or dependency that could impact participation.\n* Hearing Impairment: Uncorrected hearing loss that would limit the ability to communicate and participate in the study.\n* Non-English Speaking: Inability to participate in English-language oral and written cognitive assessments.\n* Participation in Another Study: Currently enrolled in another clinical trial that could interfere with the INSPIRE Study.\n* Life expectancy less than 3 years\n* Unwillingness to share medical and laboratory information.",true,"ALL","55 Years","85 Years",{"count":22,"type":23},2000,"ESTIMATED","INTERVENTIONAL",[26],"NA","The INSPIRE-Faith Study, initiated by the Healthy Minds Initiative, is a community-based research project aimed at demonstrating the impact of lifestyle factors on cognitive health and the prevention of dementia. Conducted in collaboration with the American College of Lifestyle Medicine, Charles Drew University, UCLA, Stanford University and Crenshaw Christian Center, this study focuses on all communities that are affected by lifestyle-dependent diseases. The study involves 2,000 participants aged 55 and older and aims to implement targeted community relevant interventions to enhance cognitive function and overall brain health.",[29],"Dementia",[29,31],"Alzheimer","RECRUITING","2026-05-26",{"date":35,"type":36},"2026-05-28","ACTUAL",{"date":38,"type":36},"2025-06-01",{"date":40,"type":23},"2028-12-01",{"name":42,"class":43},"Healthy Minds Initiative","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100627540","effect-of-counselling-using-lifestyle-medicine-assessment-tool-on-hypertensive-patients-100627540","NCT07449962","Effect of Counselling Using Lifestyle Medicine Assessment Tool on Hypertensive Patients","Effect of Counselling of Patients With Hypertension Presenting in Family Medicine Clinics Using Lifestyle Medicine Assessment Tool.","Inclusion Criteria:\n\n1. Adult patients aged 18-65 yrs with diagnosed primary\u002Fessential hypertension, defined as two or more clinic BP readings of ≥130\u002F80 (ACC\u002FAHA Guidelines).\n2. If taking anti hypertensives, then on a stable regime i.e. no recent medication change for at least ≥4 weeks.\n3. Willing and able to participate in the study.\n\nExclusion Criteria:\n\n1. Diagnosed secondary hypertension.\n2. Moderate to severe CKD (eGFR \\\u003C60 ml\u002Fmin\u002F1.73m2).\n3. Moderate to severe ischemic heart disease.\n4. Diabetes Mellitus requiring insulin.\n5. Major psychiatric disorder such as dementia or schizophrenia.\n6. Pregnancy or Lactating mother.\n7. Unable to participate in study\u002F Severe mobility limitation.","18 Years","65 Years",{"count":55,"type":23},64,[26],"The goal of this clinical trial is to learn if knowing and understanding a patient's daily habits and then giving clear advice on what changes to make can help control blood pressure better than the routine way of advising people with high blood pressure. The main questions it aims to answer are:\n\n* To learn if using the Lifestyle Medicine Assessment tool (A 21-item questionnaire) to understand the current lifestyle of people with hypertension and guide them accordingly, helps in lowering blood pressure more, as compared to routine advice?\n* To see if this way of guiding patients is more satisfactory for them then routine advice? Researchers will compare two groups of people with hypertension. One will be guided after assessing their current lifestyle with the Lifestyle Medicine Assessment Tool and one will be given routine guidance. The researchers will then see which group had better blood pressure control.\n\nParticipants will be:\n\n* Asked a few questions about their lifestyle and then they will be advised accordingly on ways to make it better.\n* They will also be asked to measure their blood pressure at home and bring the record with them when they come for their doctor's visit.",[59,60,61,62],"Lifestyle Intervention","Lifestyle Modification","Hypertension","Counselling",[64,65],"lifestyle counselling of hypertensive patients","Lifestyle Medicine Assessment Tool","NOT_YET_RECRUITING","2026-04-25",{"date":69,"type":36},"2026-04-30",{"date":71,"type":23},"2026-06",{"date":73,"type":23},"2027-02",{"name":75,"class":43},"Indus Hospital and Health Network",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":18,"minAge":84,"maxAge":53,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":44},"100496457","phase-4-metformin-for-antipsychotic-induced-weight-gain-in-adults-with-intellectual-disability-100496457","NCT05744479","Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability","Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability: A Double-Blind Randomized Control Trial","METIDD","Inclusion Criteria:\n\n* Stable outpatients\n* Age 16-65 years\n* Diagnosed with an IDD\n* On maintenance treatment with an antipsychotic (stable dose for ≥3 months).\n* BMI must be ≥30 kg\u002Fm2, OR ≥27 kg\u002Fm2 with at least one weight-related comorbidity (treated or untreated) such as: hypertension, dyslipidaemia, obstructive sleep apnea, or impaired fasting glucose, OR \\>=25 for individuals who have gained \\> 5% body weight in association with AP use.\n* Females of child-bearing age must be on one of the following regular contraceptives:\n\n  1. Agree to abstain from sex for the duration of the trial or\n  2. A barrier method of a diaphragm with spermicide and\u002For Latex condom or\n  3. An oral contraceptive agent, implantable contraceptive or an injectable contraceptive for at least six months prior to entering the study and will continue its use throughout the study, or\n  4. An intrauterine device, or\n  5. Partner has had a vasectomy at least 3 months prior to study start\n\nExclusion Criteria:\n\n* Females who are nursing, currently pregnant, or have a positive pregnancy test\n* Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, haematological, hepatic, renal, or pulmonary disease\n* Previous treatment and lack of efficacy or tolerability with metformin\n* History or diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (TD2) or fasting blood work, HbA1c \\> 6.5%\n* History of metabolic acidosis or lactic acidosis\n* Treatment with weight-lowering agents\n* Medications with significant renal impact\n* Major medical or surgical event in the preceding 3 months\n* Acute suicidal risk.\n* Moderate to severe substance use disorder, other than caffein or nicotine use disorder","16 Years",{"count":86,"type":23},100,[88],"PHASE4","People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease. While antipsychotics contribute to this problem, their use is necessary and appropriate in a significant subgroup of individuals with IDD. Exercise and diet interventions have limitations and may not be sufficient, requiring effective adjunctive pharmacological approaches to target obesity and related comorbidities in IDD. However, persons with IDD treated with antipsychotics are systematically excluded from clinical trials hindering development of evidence to help guide safe and effective treatment of these comorbidities. Moreover, evidence from other disorders cannot be extrapolated to IDD given inherent biological differences between disorders. This trial will address the identified gaps, which extend beyond cardiovascular morbidity and negatively impact psychosocial outcomes, in a hugely underserviced population.This is the the first RCT (randomized control trial) to examine the efficacy of metformin in overweight or obese adults with IDD who have experienced antipsychotic-induced weight gain. By generating efficacy data for a very accessible and scalable intervention, allows for guideline and implementation strategies to address a recalcitrant health problem.",[91,92,93],"Intellectual Disability","Developmental Disability","Obesity",[91,92,93,95],"Metformin","2026-03-26",{"date":98,"type":36},"2026-03-31",{"date":100,"type":36},"2023-02-28",{"date":102,"type":23},"2027-03-01",{"name":104,"class":43},"Centre for Addiction and Mental Health",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":24,"phases":114,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":44},"100489449","phase-2-single-nuclei-rna-seq-to-map-adipose-cellular-populations-and-senescent-cells-in-older-subjects-100489449","NCT05653258","Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects","Single Nuclei RNA-sequencing to Map Adipose Cellular Populations and Senescent Cells in Older Subjects","Inclusion Criteria:\n\n1. Both Sexes\n2. Age: younger lean group 18-30 years with BMI 18.5-24.9 kg\u002Fm2; younger obese group 18-30 with BMI 30.0 -39.9; older obese group ≥ 65 years with BMI 30.0-39.9\n3. All races and ethnic groups\n4. Community dwelling\n5. Sedentary (≤1.5 h of exercise per week)\n6. Nondiabetic (fasting plasma glucose \\\u003C 126 mg\u002Fdl, 2-h glucose during oral glucose tolerance test (OGTT) \\\u003C 140mg\u002Fdl, and A1c \\\u003C 6.5%\n7. For all female participants who are women of childbearing potential (WOCBP), who are not pregnant or breast feeding, at least one of the following conditions must apply:\n\n   A documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy Use of a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), preferably with low user dependency (implantable progesterone-only hormone contraception, intrauterine hormone releasing system, bilateral tubal occlusion, vasectomized partner) during the intervention period of the study and for at least 30 days after the last dose of study intervention to eliminate any reproductive safety risk of the study drug.\n\n   Use of a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with high user dependency, (oral\u002Fintravaginal\u002Finjectable combined estrogen and progesterone contraception, oral\u002Finjectable progesterone only hormone contraception, sexual abstinence) during the intervention period and for at least 30 days after the last dose of study intervention to eliminate any reproductive safety risk of the study drug. In addition to the highly effective methods: male or female condom with or without spermicide; cervical cap, diaphragm, or sponge with spermicide; a combination of male condom with either cervical cap, diaphragm, or sponge with spermicide.\n8. ECG value after 10 minutes of resting in the supine position in the following ranges:\n\n120ms\\\u003CPR\\\u003C220ms: QRS\\\u003C120ms; QTc\\\u003C430ms for males and QTc\\\u003C450ms for females and normal ECG tracing, unless the investigator considers the ECG abnormality to be not clinically relevant.\n\nExclusion Criteria:\n\n1. Diabetes, clinically diagnosed or HbA1c \\> 6.5% and\u002For fasting plasma glucose \\> 126 mg\u002Fdl and\u002For use of anti-diabetic medications.\n2. Participating in \\> 1.5 h of structured exercise\u002Fweek\n3. Unstable weight (\\>3% change in last 3 months)\n4. Neurological, musculoskeletal, or other conditions that may limit subject's ability to complete study physical assessment and training\n5. Active autoimmune\u002Finflammatory disease including: rheumatoid arthritis, multiple sclerosis, systemic lupus erythematous, inflammatory bowel disease\n6. Laboratory parameters outside the normal range:\n\n   * impaired kidney function (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m² as calculated by the CKD-EPI equation);\n   * impaired liver function (AST or ALT level \\> 2 times upper limit of normal (ULN);\n   * total Bilirubin level \\> 1.5 times ULN;\n   * TSH \\> 1.5 times ULN or \\\u003C lower limit of normal (LLN);\n   * Hemoglobin \\\u003C10.0 g\u002Fdl; Platelets \\\u003C125,000 cell\u002Fmm³;\n   * Platelets \\\u003C 125,000 cell\u002Fmm³\n   * Prothrombin time (PT) \\> 1.0 times ULN\n   * Partial prothrombin time (PTT) \\> 1.0 times ULN.\n7. Active gastrointestinal disease; coagulopathy; GI bleed within 6 months\n8. Clinically significant heart disease (e.g. NYH Classification \\>II; ischemia)\n9. Peripheral vascular disease (claudication)\n10. QTc prolongation \\>45 msec\n11. Use of anti-arrhythmic medications known to cause QTc prolongation, anti-platelet or anti-coagulant medication (see section 5.3)\n12. Use of quinolone antibiotics or any other drugs that may prolong the QTc interval (see section 5.3)\n13. Pulmonary disease (COPD), severe asthma or exercise-induced asthma\n14. Recent systemic or pulmonary embolus\n15. Uncontrolled blood pressure (systolic BP\\>170, diastolic BP\\>95 mmHg)\n16. Smoking, alcohol use (history of regular alcohol consumption exceeding 7 drinks\u002Fweek for female participants or 14 drinks\u002Fweek for male participants. 1 drink = 5 ounces \\[150ml\\] of wine or 12 ounces \\[360ml\\] of beer or 1.5 ounces \\[45ml\\] of hard liquor) or recreational drug use (other than marijuana)\n17. Pregnant or breastfeeding\n18. Postmenopausal women new (within 6 months) to systemic hormone replacement therapy\n19. Previous bariatric surgery\n20. History of stroke with motor disability\n21. Recent (3 years) treated cancer other than basal cell carcinoma\n22. Acute or chronic infection\n23. Medication that might interfere with metabolic studies (weight loss medication, systemic steroids, immunosuppressants) within 6 months (see section 5.3)\n24. Potentially senolytic agents within the last 6 months: fisetin, quercetin, luteolin, dasatinib, piperlongumine, or navitoclax (see section 5.3)\n25. History of allergy to dasatinib, quercetin and\u002For lidocaine.\n26. Concurrent enrollment in another interventional trial.",{"count":113,"type":23},160,[115,116],"PHASE2","PHASE3","All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular\u002Fmolecular profiling via snRNA-seq and metabolic\u002Fphysiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms: lifestyle intervention (n=24), senolytics (n=24), or placebo (n=24).",[93,119],"Healthy Lifestyle",[121,122,123],"Lifestyle intervention","Single RNA sequencing","Cell Senescence","2026-03-16",{"date":126,"type":36},"2026-03-18",{"date":128,"type":36},"2023-10-17",{"date":130,"type":23},"2028-02-01",{"name":132,"class":43},"Cedars-Sinai Medical Center",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":17,"sex":140,"minAge":52,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":24,"phases":144,"briefSummary":145,"conditions":146,"keywords":150,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":44},"100589008","phase-2-effectiveness-study-of-a-lifestyle-intervention-versus-metformin-in-mothers-with-recent-gestational-diabetes-100589008","NCT06948825","Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes","GooDMomS2","Inclusion Criteria:\n\n* Mothers between 8 weeks and 12 months postpartum from a pregnancy complicated by GDM will be recruited. The research team will begin recruiting women who are at least 8 weeks postpartum to provide time to describe the study and answer any questions. Mothers who want to participate will be enrolled in the study between 12 weeks and 12 months postpartum.\n* BMI of 25 kg\u002Fm2 to 45 kg\u002Fm2\n* Singleton delivery\n* Participants must also have a working cell phone, be willing to accept email or text messages attend Zoom calls, and be willing to be potentially randomized to drug therapy with Metformin.\n\nExclusion Criteria:\n\n* Pregnant or planned pregnancy within the next 6 months.\n* Participation in any other weight loss program or taking weight loss medication.\n* Normal or underweight BMI (BMI \\\u003C 24.9 kg\u002Fm2)\n* Multi-fetal (twins or triplets) gestation\n* Women with type 1 or type 2 diabetes, malignancy, other serious co-morbidities (advanced kidney disease, NYHA class 3-4 CHF, advanced COPD), schizophrenia or other major psychiatric disease, and substance abuse or AIDS.\n* Women whose infants have significant medical conditions, such as congenital heart disease, renal impairment, or hepatic impairment.","FEMALE","45 Years",{"count":143,"type":23},60,[115],"The goal of this clinical trial is to evaluate the effectiveness of a 6-month lifestyle intervention compared to Metformin in postpartum women who have delivered a singleton, live born infant within the last 12 weeks to 1 year and had a pregnancy complicated by gestational diabetes. The main question this study aims to answer is:\n\nIs a Lifestyle Intervention or Metformin more effective for weight loss in postpartum women with recent gestational diabetes?\n\nResearchers will compare a 6-month Lifestyle Intervention and Metformin to see if either intervention is more effective in achieving weight loss and improving health outcomes.\n\nParticipants will:\n\n* Attend an in-person baseline visit to receive a Bluetooth-enabled scale and Fitbit, have blood drawn for testing, and have their height, weight, and blood pressure measured. Participants will also be asked to bring in their infant, and the study team will measure the infant's weight and length.\n* Track diet, physical activity, and weight using the Fitbit and Looseit! apps.\n* Attend weekly online group sessions for the first 4 weeks, then biweekly sessions.\n* If not meeting weight loss goals, be randomized to either Enhanced Lifestyle Intervention or Metformin arms of the study.\n* If randomized to Metformin, participants will attend one in-person meeting with the study provider, get blood drawn for testing, and undergo a urine pregnancy test before starting the medication.\n* Continue with biweekly group sessions or have regular check-in calls.\n* If randomized to the Enhanced Lifestyle Intervention, participants will get a free Instacart membership, a 1:1 session with the study health counselor focused on meal planning and free grocery delivery once a week for the remainder of the study.\n* Participants will meet every other week via Zoom with the health counselor and other participants in the enhanced lifestyle arm.\n* At the end of the 6 months, all participants will come for an in-person visit to get blood drawn for testing. Participants will also be asked to bring in their infant, and the study team will measure the infant's weight and length.",[147,148,149],"Weight Loss","Gestational Diabetes Mellitus in Pregnancy","Postpartum Care",[151,152,153],"diabetes prevention","gestational diabetes","lifestyle intervention","2026-01-12",{"date":156,"type":36},"2026-01-13",{"date":158,"type":36},"2025-10-27",{"date":160,"type":23},"2026-11",{"name":162,"class":43},"George Washington University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":170,"targetDuration":4,"studyType":24,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":44},"100619096","phase-4-xiaojin-pillneixiao-luoli-pill-for-the-treatment-of-thyroid-nodules-100619096","NCT07340177","Xiaojin Pill\u002FNeixiao Luoli Pill for the Treatment of Thyroid Nodules","An Open-label, Multicenter, Randomized Controlled Clinical Trial of Xiaojin Pill\u002FNeixiao Luoli Pill for the Treatment of Thyroid Nodules","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Diagnosed with single or multiple thyroid nodules confirmed by high-resolution ultrasound, with at least one measurable nodule.\n* Thyroid nodules meeting one of the following criteria:\n* ACR TI-RADS category 3 with a maximum nodule diameter ≥ 1.0 cm; or\n* ACR TI-RADS category 4 or 5 nodules evaluated by fine-needle aspiration and assessed as low-risk papillary thyroid carcinoma, suitable for active surveillance, with patient consent.\n* Normal thyroid function at baseline, defined as thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4) within the reference range.\n* Traditional Chinese medicine (TCM) syndrome differentiation consistent with liver qi stagnation, blood stasis, or phlegm-dampness syndrome.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Thyroid nodules confirmed as malignant or follicular neoplasms requiring surgical intervention, or assessed by the investigator as unsuitable for active surveillance.\n* Presence of hyperthyroidism or hypothyroidism, defined as abnormal TSH, FT3, or FT4 levels.\n* History of severe cardiovascular, hepatic, renal, hematologic, psychiatric, autoimmune diseases, or other malignancies.\n* Pregnant or breastfeeding women, or women planning pregnancy during the study period.\n* Known allergy or hypersensitivity to Xiaojin Pill, Neixiao Luoli Pill, placebo components, or any ingredients of the study medications.\n* Receipt of thyroid-related surgery, radiofrequency ablation, laser ablation, radioactive iodine therapy, or other treatments that may affect thyroid nodules within 3 months prior to enrollment.\n* Current use of medications known to affect thyroid function or thyroid nodules, such as amiodarone or lithium.\n* Poor treatment compliance or inability to complete follow-up as judged by the investigator.\n* Participation in another clinical trial during the study period.",{"count":171,"type":23},108,[88],"The goal of this clinical trial is to learn whether Xiaojin Pill or Neixiao Luoli Pill can safely treat thyroid nodules in adults aged 18 to 65 years with benign or low-risk thyroid nodules. The main questions it aims to answer are:\n\n* Does treatment with Xiaojin Pill or Neixiao Luoli Pill lower the size of thyroid nodules compared with lifestyle intervention alone?\n* Do Xiaojin Pill or Neixiao Luoli Pill improve thyroid nodule-related symptoms and ultrasound findings while remaining safe to use?\n\nResearchers will compare lifestyle intervention plus Xiaojin Pill, lifestyle intervention plus Neixiao Luoli Pill, and lifestyle intervention alone to see if adding Xiaojin Pill or Neixiao Luoli Pill works better than lifestyle intervention by itself.\n\nParticipants will:\n\n* Be randomly assigned to one of the three study groups;\n* Receive lifestyle intervention guidance throughout the study;\n* Take Xiaojin Pill, Neixiao Luoli Pill, or no study medicine for 12 weeks, depending on their group;\n* Attend follow-up visits that include thyroid ultrasound exams, blood tests to check thyroid function and safety, and symptom assessments.",[175],"Thyroid Nodules",[177],"Thyroid nodule","2026-01-05",{"date":180,"type":36},"2026-01-14",{"date":182,"type":23},"2026-03",{"date":184,"type":23},"2027-06",{"name":186,"class":43},"Zhejiang Provincial People's Hospital",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":194,"targetDuration":4,"studyType":24,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":206,"locationsCount":44},"100616807","phase-2-rutin-and-vitamin-c-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100616807","NCT07310407","Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Evaluation of the Effect of Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Inclusion Criteria:\n\n* Confirmed diagnosis of Metabolic-Associated Steatotic Liver Disease (MASLD).\n\nExclusion Criteria:\n\n* HCV infection.\n* HBV infection.\n* Patients with a history of significant alcohol consumption.\n* Autoimmune hepatitis.\n* Celiac disease (CD).\n* Wilson's disease (WD).\n* Haemochromatosis.\n* Drugs: Tamoxifen, Valproic acid, Amiodarone, Methotrexate, steroids and immunosuppressive agents, oral contraceptive pills, or drugs that can affect liver profile.\n* Hypo or hyper thyroidism.\n* Bypass surgeries.\n* TPN (Total Parenteral Nutrition).\n* Pregnant individuals or patients planning to become pregnant.",{"count":195,"type":23},120,[115],"evaluate the combined effects of Rutin and Vitamin C versus Vitamin C alone on selected oxidative stress markers, inflammation, hepatic steatosis regression, and associated metabolic parameters in patients with MASLD",[199],"NAFLD","2025-12-16",{"date":202,"type":36},"2025-12-30",{"date":204,"type":23},"2026-01-01",{"date":102,"type":23},{"name":207,"class":43},"Ain Shams University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":18,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":24,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":44},"100496050","a-study-of-endoscopic-sleeve-gastroplasty-for-obesity-in-ulcerative-colitis-100496050","NCT05739162","A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis","Endoscopic Sleeve Gastroplasty (ESG) as a Treatment Option for Obesity in Ulcerative Colitis (UC) Patients Undergoing Colectomy With Ileal Pouch Anal Anastomosis (IPAA)","Inclusion Criteria:\n\n* BMI 30-50 kg\u002Fm2 for at least 6 months prior to ESG\n* Diagnosis of UC with plans to undergo or who have already undergone colectomy as part of a plan to pursue eventual 3-stage ileal pouch anal anastomosis (IPAA)\n* Willing to adhere to the diet and behavior modifications required for ESG\n* Able to follow the visit schedule\n* Able to provide informed consent\n* If female, be either post-menopausal, surgically sterile, or agree to practice birth control during year of study and have negative serum Human Chorionic Gonadotropin (HCG) at screening\u002Fbaseline\n\nExclusion Criteria:\n\n* Prior gastric or bariatric surgery or other alteration to upper gastrointestinal anatomy which would preclude safe or technical performance of ESG\n* Current or recent (last six months) gastric or duodenal ulceration\n* Esophageal or gastric varices\n* Significant motility disorder of the esophagus or stomach\n* Large hiatal hernia measuring \\>5 cm or ≤ 5 cm and associated with severe gastroesophageal reflux\n* Severe coagulopathy, hepatic insufficiency, or cirrhosis\n* Gastric mass\n* Presence of any other medical condition which precludes safe performance of elective endoscopy such as poor general health and\u002For history of severe hepatic, cardiac, or pulmonary disease\n* Serious or uncontrolled psychiatric illness which may compromise patient understanding of procedure or compliance with follow-up visits\n* Unwilling to participate in an established diet and behavior modification program, with routine follow-up\n* Ongoing corticosteroid use at a dose of \\>5 mg daily\n* Daily use of anti-inflammatory agents such as non-steroidal medications, or anticoagulants without medical supervision\n* Alcohol or drug addiction\n* Females who are pregnant, nursing, or planning pregnancy within the next year\n* Concomitant use of or unwillingness to avoid any use of weight loss medications, weight loss supplements, or weight loss herbal preparations\n* Has a condition or is in a situation which in the investigator's opinion may put the subject at significant risk or may interfere significantly with the subject's participation in the study","22 Years","69 Years",{"count":218,"type":23},12,[26],"The purpose of this research is to gather information on the safety and effectiveness of Endoscopic Sleeve Gastroplasty (ESG) for weight loss in a population of obese UC patients undergoing colectomy with eventual IPAA.",[93,222],"Ulcerative Colitis",[224,225],"ESG","IPAA","2025-11-24",{"date":228,"type":36},"2025-12-01",{"date":230,"type":36},"2023-09-20",{"date":232,"type":23},"2027-01",{"name":234,"class":43},"Mayo Clinic",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":17,"sex":18,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":24,"phases":247,"briefSummary":248,"conditions":249,"keywords":258,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":44},"100599548","norwegian-mental-illness-heart-health-study-100599548","NCT07085923","Norwegian Mental Illness Heart Health Study","Dietary Counselling And Exercise To Combat Cardiovascular Disease Risk In Norwegian Patients With A Severe Mental Illness","NORMI-Heart","Inclusion Criteria:\n\n* Diagnosis of F20-29 (schizophrenia spectrum) or F31 (bipolar affective disorder)\n* Current use of antipsychotic medication (first- or second generation) or lithium\n* Body Mass Index \\> or = 27 kg\u002Fm\\^2\n\nExclusion Criteria:\n\nPsychiatric condition:\n\n* Inability to provide informed consent\\*\n* Acute psychiatric crisis\\*\n* Significant cognitive impairment\\* \\*These criteria will be evaluated and confirmed by the participant's primary mental health care provider before enrollment\n\nMedication initiated during the intervention period:\n\n* GLP-1 receptor agonists\n* Antihypertensive medication\n* Antidiabetic medication\n* Lipid-lowering medication\n\nAlcohol consumption:\n\n-More than 14 units per week (men) or more than 7 units per week (women)\n\nSomatic conditions:\n\n* Type 1 diabetes\n* Established cardiovascular disease\n* Body Mass Index (BMI) \\\u003C27 kg\u002Fm²\n* Pregnancy\n* Inability to perform physical exercise\n\nSomatic risk findings at baseline:\n\n* HbA1c \\>57 mmol\u002Fmol (7.4%)\n* LDL cholesterol \\>5.0 mmol\u002FL\n* Blood pressure \\>180\u002F100 mmHg\n* Active malignant disease","25 Years","70 Years",{"count":246,"type":23},70,[26],"Norwegian patients with severe mental illnesses (SMI), such as schizophrenia spectrum or bipolar disorder, lose on average 10 years of life compared to mentally healthy individuals. Much of this gap is due to heart disease. Unhealthy lifestyle habits, including poor diet and physical inactivity, contribute to higher levels of metabolic risk factors for heart disease in this population.\n\nThe goal of this clinical trial is to find out if a lifestyle program including dietary counselling and regular physical exercise can help people with SMI to improve their physical and mental health.\n\nThe main questions it aims to answer are:\n\n* Does adherence to a healthy lifestyle program lead to reduced estimated risk of heart disease?\n* Does it change lifestyle habits, body weight and composition, and metabolic risk markers over six months?\n* Can participants with severe mental illness complete a healthy lifestyle program, and do they find it acceptable?\n\nResearchers will compare two groups: one that receives the lifestyle program in addition to regular mental health care, and one that receives regular care only.\n\nDuring the six month program, participants in the lifestyle group will:\n\n* Meet with a clinical dietitian once a month for dietary counselling\n* Take part in group-based physical activity sessions once a month, and receive support to follow a personal training plan\n\nAround 70 adults will take part in the study. The results may help improve the way lifestyle support is offered to people living with severe mental illness and inform health care providers about strategies to improve physical health in this vulnerable group.",[250,251,252,253,254,255,256,257],"Cardio Vascular Disease","Metabolic Syndrome (MetS)","Severe Mental Disorder","Schizophrenia and Schizophrenia Spectrum Psychosis","Bipolar Disease Type I","Overweight and\u002For Obesity","CVD Risk Factors","Severe Mental Illness",[257,259,59,260,261,262,263,264,265,266,267],"Cardiovascular Disease","Healthy Diet","Exercise","CVD-risk","Schizophrenia","Antipsychotic Medication","Bipolar Disorder","Non-pharmacological intervention","Clinical Dietitian","2025-09-26",{"date":270,"type":36},"2025-10-02",{"date":272,"type":36},"2025-09-16",{"date":274,"type":23},"2028-06-30",{"name":276,"class":43},"Madeleine Elisabeth Angelsen",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":140,"minAge":52,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":24,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":295,"leadSponsor":297,"locationsCount":4},"100358389","bariatric-surgery-after-breast-cancer-treatment-bats-100358389","NCT03946423","BAriaTric Surgery After Breast Cancer Treatment (BATS)","BAriaTric Surgery After Breast Cancer Treatment (BATS) - A Randomized Trial of Sleeve Gastrectomy Versus Lifestyle Intervention in Women Diagnosed With Early Stage Breast and With a BMI of ≥ 35","Inclusion Criteria:\n\n* Diagnosis of breast cancer in the previous 10 years and currently disease free.\n* Completion of breast cancer treatment (radiation, chemotherapy) at least \\> 6 months prior to enrollment\n* Body mass index (BMI) of ≥ 35 kg\u002Fm2, but \\\u003C 50 kg\u002Fm2.\n* 18 through 67 years of age at enrollment\n* Deemed healthy enough to undergo bariatric surgery, if assigned intervention, as determined by a surgeon and documented in the medical record.\n* Must have insurance coverage with no exclusion for obesity related treatment or management of obesity related surgical complications - in general insurance coverage is available for persons with a BMI ≥ 35 kg\u002Fm2.\n* Anticipated ability to abide by study requirements demonstrated in part by, but not limited to, successful completion of run-in assessments.\n* Willingness to accept randomization into either interventional group.\n* Provides voluntary written consent prior to performance of any research related activities.\n\nExclusion Criteria:\n\n* Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months.\n* Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease.\n* Cardiac stress test indicating that surgery or lifestyle would not be safe.\n* 12-lead EKG indicating that surgery would not be safe.\n* Significant anemia (hemoglobin 1.0 g\u002FdL or more below normal range) or history of coagulopathy.\n* History of stomach surgery, bile duct surgery, pancreatic surgery, splenectomy, or colon resection.\n* Gastric or duodenal ulcer in the past six months.\n* History of intra-abdominal sepsis except for uncomplicated appendicitis or diverticulitis more than six months prior to enrollment.\n* Self-reported HIV-positive status, active tuberculosis, active malaria, chronic hepatitis B or C, cirrhosis, or inflammatory bowel disease.\n* Currently pregnant or nursing, or planning to become pregnant in the next 15 months.\n* History of alcohol, drug, or opioid dependency (excluding nicotine) in the past five years.\n* Active psychosocial or psychiatric problem that is likely to interfere with adherence to the protocol.\n* Deemed not an acceptable candidate by a trained psychologist.\n* Current participation in a conflicting research protocol.\n* Presence of any chronic or debilitating disease that would make adherence to the protocol difficult.\n* Gastroesophageal reflux disease requiring medications. History of endoscopy demonstrating esophagitis or Barrett's changes in the esophagus.\n* Any history of dysphagia.","67 Years",{"count":286,"type":23},40,[26],"This is a feasibility study to gain an understanding of the willingness of women with a history of early stage breast cancer and current obesity to enroll in a weight-loss study, accept an assigned intervention (bariatric surgery with lifestyle intervention or lifestyle intervention alone), and comply with the study plan for 1 year. If there is successful enrollment in this study, the plan is to use what is learned in this study to design a larger, longer-term clinical trial to look at the effect of weight loss and incidence of cancer recurrence.",[290,93],"Early-stage Breast Cancer","2025-07-23",{"date":293,"type":36},"2025-07-24",{"date":71,"type":23},{"date":296,"type":23},"2028-02",{"name":298,"class":43},"Masonic Cancer Center, University of Minnesota",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":18,"minAge":306,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":24,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":324},"100520243","phase-4-sglt2-inhibition-in-addition-to-lifestyle-intervention-and-risk-for-complications-in-subtypes-of-patients-with-prediabetes-100520243","NCT06054035","SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes - a Randomized, Placebo Controlled, Multi-center Trial","Inclusion criteria:\n\n1. Male, female or intersexualpatients aged between 35 and 75 years (including)\n2. Prediabetes (defined by one of the following: FG ≥ 100 mg\u002FdL or 2h OGTT glucose ≥ 140 mg\u002FdL)\n3. BMI ≥20 kg\u002Fm2\n4. TSH within normal range\n5. Ability to understand and follow study-related instructions\n6. Negative pregnancy test for premenopausal women (blood)\n7. Patients who are receiving thyroid replacement therapy must be on a stable treatment regimen for at least 3 months prior to the screening visit (V-1)\n8. Patients who are receiving antihypertensive medication such as mineralocorticoid receptor antagonists must be on a stable treatment regimen for at least 6 weeks prior to the screening visit (V-1)\n9. Patients who are treated antihypertensive medication such as ACE inhibitors and AT1receptor antagonists, thiazides as well as loop diuretics must be on stable treatment for at least 2 weeks\n10. Understand and voluntarily sign an informed consent document prior to any study related assessments\u002Fprocedures.\n11. Patients will not be included in the study if, in the opinion of the investigator participation will lead to an unacceptable risk to the subjects' safety or well-being\n\nExclusion Criteria\n\n1. Manifest diabetes mellitus\n2. eGFR (as calculated by the CKD-EPI equation) \\\u003C 60 ml\u002Fmin\u002F1.73 m2\n3. all glucose altering medications (including current therapy with dapagliflozin or empagliflozin or any other SGLT2-Inhibitor)\n4. Symptomatic chronic congestive heart disease\n5. New diuretic or antihypertensive medication or dosing changes within the last 2 weeks, for aldosterone antagonists within the last 6 weeks\n6. known or suspected orthostatic proteinuria\n7. any acute severe or chronic severe illness, including the following: malignant disease ongoing or \\\u003C 5 years ago, unstable cardiovascular disease or procedure within 3 months prior to enrolment or expected to require coronary revascularisation procedure\n8. history of or current therapy for congestive heart failure (NYHA III and IV), pacemaker or aortic stenosis \\> II°\n9. acute pancreatic disease (i.e. elevated lipase 3x ULN)\n10. rapidly progressing renal disease or anuria\n11. known HIV infection or positive HIV test at screening\n12. history of or planned organ transplantation\n13. history or presence of inflammatory bowel disease or other severe gastrointestinal diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis\n14. relevant hepatic disease, including, but not limited to, acute hepatitis, chronic active hepatitis, or severe hepatic insufficiency, including patients with alanine aminotransferase and\u002For aspartate aminotransferase \\> 3 x upper limit of normal and\u002For total bilirubin (TB) \\> 2 mg\u002FdL (\\> 34.2 μmol\u002FL) (patients with TB \\> 2 mg\u002FdL \\[\\> 34.2 μmol\u002FL\\] and documented Gilbert's syndrome will be allowed to participate).\n15. treatment with glucocorticoids\n16. antibiotic treatment within the last 4 weeks\n17. History of ketoacidosis\n18. history of repeated urogenital infection\n19. hemoglobinopathies, haemolytic anaemia, or chronic anaemia (haemoglobin concentration \\\u003C12.0 g\u002FdL)\n20. presence of psychiatric disorder or new intake of antidepressant or antipsychotic agents(start within last 3 months)\n21. Positive Screening for a severe depression (BDI ≥29)\n22. history of hypersensitivity to the study drug or its ingredients\n23. more than 5% weight loss in the last 3 months\n24. Pregnant or breastfeeding women\n25. Subject (male, female or intersexual) is not willing to use highly effective contraceptive methods during treatment and for 14 days (male or female) after the end of treatment (highly effective methods are defined as: combined hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence).\n\n    Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success.\n26. Current participation in other interventional clinical trials or treatment with other IMPs within five times the half-life of the drug\n27. Previous therapy with dapagliflozin or other drugs that can potentially lead to overlapping toxicities within five times the half-life of the drug\n28. Patients who do not want to be informed about accidental findings\n29. Any other clinical condition that would jeopardize subjects' safety or well-being while participating in this clinical trial\n30. Patients will not be included in the study if, in the opinion of the investigator, participation leads to an unacceptable risk to their safety and well-being","35 Years","75 Years",{"count":309,"type":23},170,[88],"More than 50% of patients with type 2 diabetes develop micro- and\u002For macrovascular complications during the course of the disease. Additionally, many patients at risk for diabetes develop metabolically driven complications including kidney and heart disease. Thus, it is of utmost importance to improve prevention of T2D and with this complications. Remission of prediabetes, i.e. normalization of hyperglycemia by means of lifestyle intervention is one of the most effective ways to prevent the development of T2D and complications. Novel sub-phenotyping analysis identified clusters of risk for diabetes associated with different complications, opening opportunities to new therapeutic approaches, despite and in addition to lifestyle changes. So far, pharmacological therapy is not indicated for patients with prediabetes. Remission of hyperglycemia associated with prediabetes during lifestyle interventions not only prevents T2D but is also linked with reduced albuminuria and lower microvascular and kidney complications. Thus, reaching normoglycemia (i.e. prediabetes remission) is important for reducing the risk of (pre-)diabetes-associated complications including micro- and even macrovascular disease. In patients with T2D, recent data show that dapagliflozin can improve diabetes remission, and thus, likely complications. However, to date no data have assessed whether or not this is also true in patients with hyperglycemia related to prediabetes which, as outlined above, already causes different complications.\n\nSubphenotyping of patients with newly onset diabetes suggests that for some individuals, it would be too late to start interventions against dagainst complications at the time of diagnosis of type 2 diabetes. Therefore, individuals at elevated risk to develop T2D and complications should receive preventive measures well before the diagnosis of T2D. This study will provide evidence whether such an early intervention contributes to the remission of hyperglycemia related to prediabetes to protect from associated complications such as renal disease. The studied population will comprise individuals who have hyperglycemia in the range of prediabetes and are thus prone to not only develop T2D, but also early nephropathy but in clinical practice do not receive medical treatment due to the early stage of the disease. These subjects will receive Dapagliflozin 10 mg or Placebo for 6 months. The placebo treatment arm reflects current practice. In order guarantee a benefit the patients in the placebo arm will receive a lifestyle intervention.",[313,314,315],"Type2diabetes","PreDiabetes","Renal Failure","2025-07-21",{"date":293,"type":36},{"date":319,"type":36},"2023-10-26",{"date":321,"type":23},"2027-09-30",{"name":323,"class":43},"University Hospital Tuebingen",9,{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":140,"minAge":52,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":24,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":347},"100349003","every-day-counts-a-lifestyle-program-for-women-with-metastatic-breast-cancer-100349003","NCT03824145","Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer","EDC","Inclusion Criteria:\n\n* Adult (≥ 18 years), female\n* Confirmed Metastatic Breast Cancer\n* Patients clinically stable with treated brain metastases are eligible\n* Written documentation from their oncologist permitting study participation\n* Determined to be \"clinically stable\" by their medical oncologist (i.e., no unintentional weight loss, no new symptoms or change in performance status for the past 4 weeks, no clinical \\[including laboratory\\] or radiologic evidence of disease progression, no recent or planned change in anti-neoplastic therapies, no reports of severe pain \\[≥ Grade 3 per the NCI CTCAE)\n* Life expectancy \\>6 months\n\n  -Written documentation from their oncologist permitting study participation\n* Access to a mobile phone\n* Understand\u002Fspeak English fluently.\n* Non-adherence to ACS nutritional or PA guidelines for cancer survivors as documented by questionnaire.\n\nExclusion Criteria:\n\n* Does not meet the above criteria.",{"count":333,"type":23},176,[26],"This multi-site study is being conducted to examine dietary and activity patterns, body composition, blood and quality of life in breast cancer patients. The study will recruit 176 women with MBC in Milwaukee (n=88) and Chicago (n=88).",[337],"Metastatic Breast Cancer","2025-04-24",{"date":340,"type":36},"2025-04-27",{"date":342,"type":36},"2022-11-01",{"date":344,"type":23},"2027-02-01",{"name":346,"class":43},"Medical College of Wisconsin",2,{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":24,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":373},"100349251","bicycle-exercise-and-lifestyle-intervention-in-newly-diagnosed-diabetes-100349251","NCT03827382","Bicycle Exercise and Lifestyle Intervention in Newly Diagnosed Diabetes","BELIFE","Inclusion Criteria:\n\n* Informed consent as documented by signature\n* Type 2 diabetes diagnosed within the last two years according to the American Diabetes Association (ADA) criteria\n* Age ≥ 18 years\n* HbA1c ≥ 7.5 %\n\nExclusion Criteria:\n\n* Clinically instable patient as defined by the physicians on duty including signs of new cardiac ischemia in the ECG, systolic blood pressure ≥ 200 mmHg, fever ≥ 38.5 °C, symptoms of SIRS or reduced vigilance.\n* Anti-diabetic medication for ≥ 24 hours\n* Inability to perform a bicycle exercise during 30 minutes\n* Previous lifestyle-intervention by an endocrinologist\n* Engagement in physical activity more than five times per week\n* Enrollment in other interventional study",{"count":356,"type":23},62,[26],"The aim of the study is to test the efficacy, feasibility, and safety of a bicycle exercise followed by an intensive lifestyle intervention for 3 months in patients with recent onset and medically untreated type 2 diabetes.",[360],"Life Style",[362,363],"Life Style Intervention","Type 2 Diabetes mellitus","2025-02-11",{"date":366,"type":36},"2025-02-14",{"date":368,"type":36},"2019-02-01",{"date":370,"type":23},"2025-12-31",{"name":372,"class":43},"University Hospital, Basel, Switzerland",3,""]